Eli Lilly Brazil — Loss Contingency Damages Awarded Value remained flat by 0.0% to $50.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 66.7%, from $30.00M to $50.00M. Over 2 years (FY 2022 to FY 2024), Brazil — Loss Contingency Damages Awarded Value shows an upward trend with a 18.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates higher financial risk and potential erosion of profitability, while a decrease suggests reduced legal exposure or successful defense strategies.
This metric quantifies the total monetary value of damages awarded against the company in legal proceedings within a spe...
Large-cap pharmaceutical companies frequently disclose these figures as part of their legal contingency reporting, often compared against industry-standard litigation reserves.
lly_segment_br_loss_contingency_damages_awarded_value| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.00M | $950.00M | $1.00B | $0.00 | $0.00 | $0.00 | $1.15B | $0.00 | $90.00M | $20.00M | $1.30B | $30.00M | $30.00M | $40.00M | $1.44B | $50.00M | $50.00M |
| QoQ Change | — | +850.0% | +5.3% | -100.0% | — | — | — | -100.0% | — | -77.8% | >999% | -97.7% | +0.0% | +33.3% | >999% | -96.5% | +0.0% |
| YoY Change | — | — | — | -100.0% | -100.0% | — | +15.0% | — | — | — | +13.0% | — | -66.7% | +100.0% | +10.8% | +66.7% | +66.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.